845616-57-1

Basic information

• Product Name: 2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine
• Synonyms: 2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine
• CAS NO: 845616-57-1
• Molecular Formula: C₁₆H₁₇F₃N₄
• Molecular Weight: 322.3281896
• Mol File: 845616-57-1.mol

Chemical Properties

• Boiling Point: 418.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.284±0.06 g/cm3(Predicted)
• PKA: 7.03±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine(845616-57-1)
• EPA Substance Registry System: 2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine(845616-57-1)

Safety Data

• Hazardous Substances Data: 845616-57-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine is used as a potential antipsychotic or antidepressant agent for its potential to modulate neurotransmitter systems and alleviate symptoms of mental health disorders.
Used in Oncology:
2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine is used as a potential anticancer agent, targeting cancer cells and potentially inhibiting their growth and proliferation.
Used in Medicinal Chemistry:
2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine is used as a compound for the development of new drugs, serving as a starting point for the synthesis of novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 7773-69-5 4-benzyl-piperazine-1-carboxamidine hydrochloride 
• 176214-18-9 N-[3-(dimethylamino)-2-(trifluoromethyl)-2-propenylidene]-N-dimethylammonium chloride 

Relevant articles and documents

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

Sulfanyl substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, R3, X, X1, and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.

Substituted acylpiperazine derivatives

The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES

A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

BENZOYL-PIPERAZINE DERIVATIVES

The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.